Current Report
Filed: 2026-01-08
Key Insights
- Tango Therapeutics reported $343 million in cash, cash equivalents and marketable securities as of December 31, 2025, indicating a strong financial position.
- The company announced the resignation of Barbara Weber, M.D. as President and CEO, and the appointment of Malte Peters, M.D. as the new President and CEO, effective January 8, 2026.
- Tango Therapeutics granted Malte Peters, the new CEO, a compensation package including a base salary of $720,000, a target cash bonus of 60%, and equity awards of stock options and restricted stock units.